Table 1. Baseline Characteristics.
| Participant Characteristics | No. (%) | P Value | ||
|---|---|---|---|---|
| Healthy Volunteers (n = 20) | Posttransplant (n = 44) | |||
| Receiving Immunosuppression (n = 23) | Not Receiving Immunosuppression (n = 21) | |||
| Age, median (range), y | 32.9 (23.0-45.8) | 34.3 (18.3-48.1) | 32.2 (18.3-49.9) | .40 |
| Race/ethnicity | ||||
| White | 12 (60.0) | 8 (34.8) | 12 (57.1) | .01 |
| Black | 2 (10.0) | 11 (47.8) | 1 (4.8) | |
| Asian | 5 (25.0) | 1 (4.3) | 5 (23.8) | |
| Hispanic | 1 (5.0) | 3 (13.0) | 3 (14.3) | |
| Education | ||||
| High school | 0 (0) | 4 (17.4) | 6 (28.6) | .045 |
| Some college | 3 (15) | 5 (21.7) | 5 (23.8) | |
| College graduate | 5 (25) | 10 (43.5) | 5 (23.8) | |
| Graduate school | 10 (50) | 3 (13.0) | 3 (14.3) | |
| Unknown | 2 (10) | 1 (4.2) | 2 (9.5) | |
| Relationship | ||||
| Never had sex | 1 (5) | 2 (8.7) | 3 (14.3) | .80 |
| Currently sexually active | 14 (70) | 9 (39.1) | 13 (61.9) | .13 |
| Smokinga | 3 (15) | 3 (13) | 4 (19) | .91 |
| Evidence of HPV infection at baselineb | 5 (25) | 6 (26.1) | 7 (33.3) | .83 |
| HPV-negative at baselinec | 2 (10) | 9 (39.1) | 7 (33.3) | .08 |
| HPV type–specific testingd | 2 (10) | 1 (4.2) | 1 (4.8) | .68 |
| Posttransplant Patients, Transplant Characteristics | All Posttransplant (n = 44) | |||
| Age at transplant, median (range), y | 31.7 (9.7-49.2) | 32 (11.1-46.8) | 27.6 (9.7-49.2) | .17 |
| Transplant indication | ||||
| Malignant | 27 (61.4) | 14 (60.9) | 13 (61.9) | >.99 |
| Nonmalignant | 17 (38.6) | 9 (39.1) | 8 (38.1) | |
| Graft source | ||||
| Bone marrow | 7 (16.2) | 3 (13) | 4 (20) | .54 |
| Peripheral blood stem cells | 35 (81.4) | 20 (87) | 15 (75) | |
| Cord | 1 (2.3) | 0 (0) | 1 (5) | |
| HLA matching (fully matched) | 32 (72.7) | 15 (65.2) | 17 (80.9) | .32 |
| Donor relationship (related) | 30 (68.2) | 17 (73.9) | 13 (61.9) | .52 |
| Donor age, median (range), y | 33 (14-66) | 38 (14-66) | 28 (15-59) | .14 |
| Donor sex (female) | 22 (50) | 11 (47.8) | 11 (52.4) | .76 |
| Conditioning intensity (myeloablative) | 14 (31.8) | 6 (26.1) | 8 (38.1) | .52 |
| T cell depletion | 16 (36.4) | 8 (34.8) | 8 (38.1) | >.99 |
| Time since transplant, median (range), y | 2.1 (0.4-12.6) | 1.3 (0.4-7.5) | 2.3 (0.4-12.6) | .31 |
| Donor lymphocyte infusion | 8 (18.2) | 4 (17.4) | 4 (19.0) | >.99 |
| Acute GVHD | ||||
| Grade II-IV | 13 (29.5) | 8 (34.8) | 5 (23.8) | .51 |
| Grade III-IV | 4 (9.1) | 4 (17.4) | 0 (0) | .11 |
| Chronic GVHD | 21 (47.7) | 12 (52.2) | 9 (42.9) | .56 |
| Extensive | 13 (29.5) | 8 (34.8) | 5 (23.8) | .51 |
| Genital | 10 (22.7) | 6 (26.1) | 4 (19.0) | .72 |
| Rituximab use | 8 (18.1) | 4 (17.4) | 4 (19.0) | >.99 |
| IgG, median (IQR), mg/dL | 941 (674-1185) | 1020 (694-1246) | 869 (552-1057) | .44 |
| CD19, median (IQR), No. of cells/uL | 302 (105-547) | 275 (56-564) | 306 (200-501) | .58 |
| CD4, median (IQR), No. of cells/uL | 511 (269-716) | 403 (232-721) | 593 (371-709) | .34 |
Abbreviations: ASCCP, American Society for Colposcopy and Cervical Pathology; CD, cluster of differentiation; GVHD, graft vs host disease; HLA, human leukocyte antigen; HPV, human papillomavirus; IgG, immunoglobulin G; IQR, interquartile range.
SI conversion factor: To convert IgG to grams per liter, multiply by 0.01.
All smokers are former smokers.
Abnormal cytology (ASCCP criteria), HPV anogenital lesions, or HPV-positive on pooled testing for either high- or low-risk types.
HPV-negative at baseline includes negative cytology results, negative for cervical low or high-risk HPV DNA on pooled testing, and negative HPV-6/-11/-16/-18 antibodies at enrollment and no prior history of cervical or lower genital tract treatment.
HPV DNA type–specific testing for HPV-6, HPV-11, HPV-16, HPV-18 in oral or cervical specimens.